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Most neuroactive drugs were discovered through unexpected behavioral observations.
Systematic behavioral screening is inefﬁcient in most model organisms. But, automated
technologies are enabling a new phase of discovery-based research in central nervous
system (CNS) pharmacology. Researchers are using large-scale behavior-based chemical
screens in zebraﬁsh to discover compounds with new structures, targets, and functions.
These compounds are powerful tools for understanding CNS signaling pathways. Substan-
tial differences between human and zebraﬁsh biology will make it difﬁcult to translate these
discoveries to clinical medicine. However, given themolecular genetic similarities between
humans and zebraﬁsh, it is likely that some of these compounds will have translational
utility. We predict that the greatest new successes in CNS drug discovery will leverage
many model systems, including in vitro assays, cells, rodents, and zebraﬁsh.
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INTRODUCTION
At a recent course on neurotherapeutic drug discovery (sponsored
by the National Institutes of Health) the keynote speaker joked
that if he were trying to be rational, he would not be trying to dis-
cover neuroactive drugs. His point was that drug discovery is often
much more empirical than rational. Someday, when researchers
understand the biochemical mechanisms of psychiatric disease, it
may be possible to discover neuroactive drugs based on rational
therapeutic hypotheses. Until then, phenotypic assays provide an
alternative approach. Behavior-based drug discovery is effective,
but it needs to be more efﬁcient.
Researchers can discover new drugs without understanding
how they work. Neuroactive compounds including antipsychotics,
antidepressants, and anxiolytics are among the top selling pre-
scriptiondrugs (Alonso et al., 2004; Gu et al., 2010;Alexander et al.,
2011; Mojtabai and Olfson, 2014; Olfson et al., 2014). We know
some details about how these drugs affect different neurotransmit-
ter signaling pathways. But nobody really knows how these simple
molecules change our moods, thoughts, and emotions. Target-
based approaches to central nervous system (CNS) drug discovery
have been largely unsuccessful (Paul et al., 2010). However, we can
discover new drugs without understanding the details of how they
work (Irwin, 1968; Tecott and Nestler, 2004). Historically, many
neuroactive drugs were discovered despite totally incorrect thera-
peutic hypotheses (Sneader, 2005; Kokel and Peterson, 2008; Enna
and Williams, 2009). So, although drug discovery and molecu-
lar understanding often go hand in hand—it is mostly in that
order.
New technologies are changing how researchers use phe-
notypic assays to discover new drugs. Low throughput assays
have limited the ﬁeld with small sample sizes, narrow scope
and limited hypothesis testing. Many key discoveries were made
essentially by chance (Sneader, 2005; Enna and Williams, 2009).
Now, high throughput assays are enabling a discovery-based
approach that relies more on mathematical modeling and mas-
sive amounts of data (rather than theory and luck) to iden-
tify new drug leads (Schadt et al., 2009). Automated screening
platforms do not need mechanistic theories to generate large
data sets and identify correlations between compounds and
phenotype. As a result, researchers can focus on discovering
drugs and drug mechanisms as separate independent endeav-
ors. Here, we review how this data-driven approach to behav-
ioral phenomics is accelerating the pace of neuroactive drug
discovery.
HOW MANY NEUROACTIVE DRUGS ARE THERE?
“How many neuroactive drugs are there?” is a deceptively simple
question that can be surprising difﬁcult to answer. Neuroac-
tive drugs are difﬁcult to classify because relationships between
compound structure, target and phenotype are often unclear
and poorly understood. Structure-based classiﬁcation is dif-
ﬁcult because small structural changes can drastically alter a
compound’s mechanism of action. Target-based classiﬁcation is
difﬁcult because drug targets are often unknown. Even when
in vitro targets are identiﬁed, their in vivo relevance is often
unclear. One approach is to classify compounds based on behav-
ioral phenotypes or medical utility. But most phenotype-based
classiﬁcations are subjective and difﬁcult to quantify. How do
we know when a drug is an antipsychotic or an antidepressant
(Maher et al., 2011)? There are no known molecular causes or
biomarker-based diagnostics for most mental disorders (Javitt
et al., 2008) and off-label prescriptions are common (Chouinard,
2006; Alexander et al., 2011). So exactly how many neuroactive
drugs are there?
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Although the FDA lists thousands of antipsychotics, antide-
pressants and anxiolytics, most of these compounds fall into just a
few structural classes. Consider the antipsychotics. Searching the
FDALabel database for“antipsychotic”returns 1,325 hits, butmost
are mixtures and formulations of identical compounds (U.S. Food
and Drug Administration, 2014). The same search in Drugbank
returns 42 hits and most are close structural analogs of each other
(Kokel and Peterson, 2008). Chemoinformatic algorithms clus-
ter these compounds into a small number of structurally related
families (Cao et al., 2008; Backman et al., 2011; Figure 1). Like
antipsychotics, the antidepressants and anxiolytics show a similar
pattern: There are many individual drugs, but most are struc-
tural analogs of a handful of prototypes. These data suggest that
many drugs seem to discover themselves, due to the exploitation
of prototype molecules (Sneader, 1996).
Most neuroactive drug prototypes were discovered during two
broad time periods: pre-history and the mid-1900s. Both waves
of discovery coincided with the availability of new chemical
compounds alongside relatively widespread human and animal
experimentation. The ﬁrst wave of drugs, discovered in prehis-
toric times, were found by screening (ingesting) natural products
in the environment. Compounds like morphine, alcohol, nicotine,
and cocaine were identiﬁed based on their strange and unexpected
behavioral phenotypes. The second wave of drugs, discovered in
the mid-1900s, were found by screening synthetic compounds.
These drugs, including the ﬁrstmodern anxiolytics, antipsychotics
and antidepressants, were also discovered based on unexpected
behavioral phenotypes.
Behavioral phenotyping is an essential part of drug discov-
ery, but it is also the bottleneck (Figure 2). Prototype discovery
often starts with the observation of an unexpected behavioral
phenotype. Once a prototype has been identiﬁed, medicinal
chemists generate structural analogs that themselves often have
unexpected phenotypes. Researchers use these compounds to test
FIGURE 1 | Many drugs are structural analogs of each other.
Hierarchical cluster tree of 42 drugs labeled as “antipsychotic” in the
Drugbank database. Five major families are indicated with ovals. Each
family stems from a single prototype molecule.
FIGURE 2 | Behavioral phenotyping is a key bottleneck in drug
discovery. Although there is an abundance of small molecules from nature,
medicinal chemistry, and target-based screening only a very small number
are ever tested in behavioral assays, limiting the drug discovery process.
therapeutic hypotheses and search formechanistic understanding.
When molecular targets are identiﬁed, researchers search for new
ligands that trigger a new round of behavioral phenotyping. In
target-based approaches, behavioral phenotyping is deferred until
later in the process. Ultimately, the ﬁnal step of determining efﬁ-
cacy in humans is also a matter of behavioral phenotyping. The
process is incredibly effective and has generated most drugs that
we use today. Medicinal chemistry can efﬁciently generate thou-
sands of structural analogs; technologies for in vitro screening are
ultra high-throughput. But, decades-old approaches to behavioral
phenotyping throttle the drug discovery engine.
WHAT DO ZEBRAFISH DO?
The zebraﬁsh model system enables researchers to combine
complex behavioral phenotyping with high-throughput chemical
screening. Like humans, ﬁsh are vertebrate animals with complex
brains and behaviors. But unlike humans, ﬁsh are small enough
to ﬁt in 96-well plates and they easily absorb compounds dis-
solved in the water. These features make zebraﬁsh uniquely well
suited for phenotype-based neuroactive drug discovery and enable
researchers to scale complex behavioral assays to high-throughput
formats.
A frequently asked question about behavior-based drug discov-
ery in zebraﬁsh is “What do zebraﬁsh do?” Personality disorders,
depression, and anxiety seem like some of the most complex phe-
notypes imaginable. Fish do not suffer from these feelings the
same way that people do. So, the idea of using ﬁsh to discover neu-
roactive drugs can seem counterintuitive. We tend to think about
zebraﬁsh behavior in two different ways: where as some ﬁsh behav-
iors resemble some human behaviors, many others lack obvious
human correlates.
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Anthropomorphic assays in ﬁsh are very powerful. We imme-
diately empathize with familiar behaviors and their circuitry and
mechanisms are likely to be relatively well conserved. For example,
researchers use circadian cycles in zebraﬁsh locomotor activ-
ity to study mechanism that control sleep behaviors in humans
(Prober et al., 2006; Zhdanova, 2006; Yokogawa et al., 2007; Rihel
et al., 2010). Researchers also use zebraﬁsh behavior to study
pain (Prober et al., 2008), fear (Speedie and Gerlai, 2008; Aget-
suma et al., 2010; Mathuru et al., 2012), learned helplessness (Lee
et al., 2010), feeding (Gahtan et al., 2005; Del Bene et al., 2010;
Bianco et al., 2011), courtship (Darrow and Harris, 2004), learning
(Valente et al., 2012), vision (Emran et al., 2007), hearing (Gleason
et al., 2009), touch (Lowet al., 2010,2011,2012), social interactions
(Pérez-Escudero and de Polavieja, 2011; Mahabir et al., 2013; Qin
et al., 2014), anxiety (Stewart et al., 2012), and decision making
(Arganda et al., 2012).
By contrast, it is more difﬁcult to empathize with ﬁsh-
speciﬁc phenotypes. The practical implications of understand-
ing fundamental ﬁsh behaviors are not always obvious. And
it is easy focus on their differences rather then their similar-
ities. Nevertheless, neuroactive drugs affect ﬁsh behavior in
speciﬁc and reproducible ways via conserved molecular mecha-
nisms. Adult zebraﬁsh, differentially change their swimming and
three-dimensional tank diving behaviors in response to many
neuroactive compounds (Cachat et al., 2011; Grossman et al.,
2011; Stewart et al., 2011; Kyzar et al., 2012a, 2013; Williams
et al., 2012; Robinson et al., 2013; Stewart and Kalueff, 2014).
In larvae, ﬁsh speciﬁc behaviors like spontaneous swimming
(Wyart et al., 2009), the optokinetic reﬂex (Emran et al., 2007)
and photomotor response (Kokel et al., 2013b) can be used to
understand neuronal signaling, rapidly identify novel neuroac-
tive compounds and predict their mechanisms of action (Kokel
et al., 2010; Rihel et al., 2010). The key challenge is learning how
to decode complex patterns of behavior to understand which
pathways are being modulated—and how they may affect human
health.
A DISCOVERY-BASED APPROACH
Some of the most exciting developments in behavioral phenomics
are coming from two very differentmodels: humans and zebraﬁsh.
Compared to other animals, human behaviors are probably the
most complex, variable and challenging to measure. So it is some-
what surprising that human behavioral phenomics is advancing
so rapidly. One reason is that substantial investments by inter-
net technology companies have increased the scale of digital
record keeping and chemobehavioral phenotyping. Large medical
databases link people’s genotype, phenotype andprescriptiondrug
records. Researchers are mining these databases to identify unan-
ticipated drug side effects and repurpose drugs for new indications
(Dudley et al., 2010).
Human behavioral phenomics is a powerful way to approach
drug repurposing, but it cannot be used for chemical screen-
ing. Governmental and institutional regulations limit large-scale
human studies to compounds that are already approved by the
FDA (thankfully). Researchers will need other model organisms,
like zebraﬁsh, to systematically discover new molecular entities.
Until recently, tools for high throughput behavioral phenotyping
were unavailable. But new technologies are changing the drug
discovery landscape.
AUTOMATED SOLUTIONS
Automated technologies are making behavior-based chemical
screening in zebraﬁsh amore effective, efﬁcient and systematicway
to discover neuroactive compounds. Three aspects of automation
are changing the ﬁeld of behavior-based drug screening: robotics,
analytics, and academic industrial collaboration. These changes
are a small part of larger global trends in computing technology.
As sophisticated processors, programming languages, and rapid
prototyping tools become more accessible, individual scientists
and small academic laboratories are innovating alongside larger
biotechnology and pharmaceutical companies.
Robotic solutions are growing to meet nearly every early
step of the screening process including ﬁsh breeding, sorting,
and phenotyping. Robotic aquaculture racks automate feeding
cycles and monitor water quality. Specialized breeding tanks pro-
duce thousands of synchronized embryos (Adatto et al., 2011).
Flow cytometry platforms sort zebraﬁsh into 96-well plates. And
imaging platforms automate morphological and behavioral phe-
notyping (Burgess andGranato, 2007a; Pardo-Martin et al., 2010a,
2013; Ahrens et al., 2012; Engert, 2012; Wittmann et al., 2012).
For example, researchers have developed an elegant and pow-
erful (freely available) software package, FLOTE, for automated
tracking of precise kinematic events in larval zebraﬁsh (Burgess
and Granato, 2007a). The software has already been used to ana-
lyze startle modulation, light adaptation, and navigation (Burgess
and Granato, 2007a,b; Burgess et al., 2009, 2010; Jain et al., 2011;
Fernandes et al., 2012). The software has also been used to ﬁnd
compounds that modulate memory formation in larval zebraﬁsh
(Wolman et al., 2011). Although not yet used for drug screen-
ing, recent advances in whole-brain functional imaging record
patterns of ﬁring activity of individual cells in large popula-
tions of neurons (Ahrens et al., 2012, 2013; Kokel et al., 2013b;
Muto et al., 2013; Satou et al., 2013; Portugues et al., 2014) and
will likely add massive amounts data to the behavioral phar-
macology ﬁeld. As behavioral datasets grow, researchers are
applying new analytical approaches to explore, organize, and dis-
cover correlations between phenotypic patterns and compound
treatments.
Academic-industrial partnerships are improving zebraﬁsh phe-
notyping and phenotype-based approaches to drug discovery. The
innovations ﬂow bothways, from academia to industry and indus-
try to academia. Acquifer (http://www.acquifer.de), a new biotech
company with roots in academic automated zebraﬁsh phenotyp-
ing, is developing network platforms for managing huge amounts
of data from zebraﬁsh phenotypic screens. Commercial imaging
platforms, like the Vertebrate Automated Screening Technology
marketed is based on academic innovations (Pardo-Martin et al.,
2010b, 2013; Chang et al., 2012). When equipment is too expen-
sive, academic bioinstrumentation laboratories are working to
develop more affordable do-it-yourself kits (Alper, 2009; Marzullo
and Gage, 2012). As sophisticated rapid prototyping tools become
more accessible (like 3D printers, open source programming lan-
guages, and cheap microcontrollers) the pace of innovation is
accelerating.
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SCALING BEHAVIORAL DATABASES INTO CONNECTIVITY
MAPS
Today, database-linked tools for analyzing gene expression data
and behavioral data look very different. Behavioral databases tend
to be designed for ﬁnding and summarizing data via search ﬁeld
descriptors like compound name, genes name and strain name.
For example, the Zebraﬁsh Neurophenome Database (ZND) is a
publically available database designed to provide a comprehensive
resource of neurobehavioral phenotypes in adult zebraﬁsh (Green
et al., 2012; Kyzar et al., 2012b; Kalueff et al., 2013). To search
the ZND, a researcher uses drop-down ﬁelds to select investigator
and drugs of interest to experimental results and drug effects that
are often presented as textual descriptions. Similarly, large-scale
mouse phenotyping projects like the Mouse Phenome Database
(MPD) at The Jackson Laboratory allow users to ﬁnd, visualize
and analyze mouse behavioral phenotypes across different strains
and conditions (Maddatu et al., 2012). The MPD stores a large
amount of standardized, quantiﬁable and comparable data (like
weight and grip strength). The MPD also provides a variety of
tools to analyze results (including tools to ﬁnd strains that best
ﬁt phenotypic criteria). But, as phenotypic databases grow ever
larger, they will enable more complex data-driven queries.
Given sufﬁciently rich behavioral phenotyping, it should be
possible to build a connectivitymap to systematically identify neu-
roactive compounds and sort them into phenotypic classes. For
example, the Connectivity Map is designed to use gene expres-
sion data as a discovery framework by allowing researchers to use
gene expression signatures to query the data for closely related
perturbagens (Lamb et al., 2006; Lamb, 2007). As a result, one can
use the data itself to identify correlations, perform cluster analy-
ses and identify outliers. Analyses that were originally developed
for applications like speech recognition and social networking
can just as easily be applied to analyzing zebraﬁsh phenotypes.
And these analyses allow new questions about large diverse data
sets. We imagine that someday soon, it may be possible to query
large behavioral databases with BLAST-like and speech recogni-
tion tools. This could allow researchers to identify all compounds
with similar behavioral phenotypes, link genetic mutants to small
molecule treatments and identify new treatments with totally
novel phenotypes. Will it be possible to identify just the right
pattern of ﬁsh behaviors to accurately identify drugs with com-
plex activities inhumans (like antipsychotics and antidepressants)?
Future studies may provide the answer.
WHAT ARE WE LIKELY TO FIND?
Given that so few compounds have been tested in animals,
large-scale behavioral screens are almost guaranteed to identify
new neuroactive compounds. These studies will provide high-
resolution maps of how small molecules affect the brain and
behavior. But what kinds of compounds are likely to be discov-
ered? Are we really likely to identify new compounds with new
mechanisms of action? Or just more of the same kinds of drugs
we already have? The data supports both arguments.
On the one hand, one could argue that behavior-based drug
screening has been saturated: Multiple classes of antipsychotics,
antidepressants, and anxiolytics have already been identiﬁed. One
possibility is that the low throughput non-systematic approaches
employed in the past have already identiﬁed all the neuroactive
drugs worth discovering. Alternatively, it is interesting to speculate
that compounds with antipsychotic, antidepressant and anxiolytic
effects may be relatively common. If so, large-scale screens would
likely identify a variety of new psychotropic drug prototypes with
a range of phenotypic and mechanistic proﬁles, including totally
new structures, mechanisms, and phenotypes.
Large zebraﬁsh behavior-based chemical screens are already
identifying a variety of new compounds. Some of ﬁrst neuroactive
compounds to be discovered in zebraﬁsh, str1, and str2, were novel
acetylcholinesterase inhibitors (Kokel et al., 2010). These com-
pounds were newmolecular entities, but they were not ﬁrst in class
compounds. These compounds may provide modest advantages
over current treatment options. But identifying novel structures
with novel targets and mechanisms would have a greater impact.
One potential way to identify compounds with novel mechanisms
is to identify compounds that cause outlier phenotypes in behav-
ioral databases. If one compound in ten thousand causes a unique
behavioral phenotype, this suggests it may be working through a
new (and rare) mechanism of action. For example, a new kind of
light controllable rapidly reversible TrpA1 ligand, optovin, was
recently discovered in just this way (Kokel et al., 2013a). Sev-
eral novel light activated molecules have been developed using
zebraﬁsh behavioral readouts (Szobota et al., 2007; Janovjak et al.,
2010; Levitz et al., 2013). This suggests that truly novel compounds
are waiting to be found, if only we use the right methods to look
for them.
MODIFIER SCREENS: CHEMICAL AND GENETIC MODELS
Although wild-type phenotypes may be useful for identifying cer-
tain compounds, we can also use chemical and genetic tools to
model speciﬁc disease states. These disease models combine the
advantages of unbiased phenotypic screening with readouts that
are speciﬁcally designed to target certain kinds of compounds. In
one recent example, researchers identiﬁed a zebraﬁsh mutant (in
the Scn1a gene) and then used this model to screen for poten-
tial treatments for Dravet syndrome (caused by mutations in the
homologous human gene; Baraban et al., 2013). These researchers
identiﬁed an FDA approved compound that suppressed the ﬁsh
phenotype, suggesting that the approach may be a powerful way to
identify therapeutics for this speciﬁc disorder. This work elegantly
illustrates the potential for genetic models in zebraﬁsh to identify
desperately needed targeted therapeutics with potential utility in
humans. One can imagine many variations on this theme. CRISP-
Cas technology is revolutionizing zebraﬁsh researchers’ ability to
efﬁciently generate knockout and knock-in models (Hwang et al.,
2013a,b; Auer et al., 2014). Transgenic overexpression models phe-
nocopy aspects of neurodegenerative and other dominant diseases
(Bai et al., 2007; Olson et al., 2010). And, due to the ease of
chemical manipulations, researchers have run large-scale modi-
ﬁer screens in chemically treated disease models (Baraban et al.,
2005).
WHOLE ORGANISM PHENOTYPING: BLOOD–BRAIN BARRIER
AND TOXICOLOGY
Researchers can expand phenotypic readouts to encompass almost
any aspect the organism including blood–brain barrier (BBB),
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toxicity, and cardiovascular readouts. Larval zebraﬁsh develop a
functional BBB with size exclusion and transport pumps includ-
ing those that are similar to mammals (Jeong et al., 2008). So
researchers have some reason to believe compounds with CNS
activity in ﬁsh may also penetrate the BBB in mammals. Similarly,
potentially toxic compounds can be screened for unwanted and
unexpected toxic or cardiovascular side effects. One could poten-
tially capture data on zebraﬁsh development, behavior and heart
rate simultaneously in a high-throughput and automated fash-
ion. Because researchers can apply diverse phenotyping assays,
zebraﬁsh are an exciting model for toxicology in addition to drug
discovery.
THE CHALLENGE OF TRANSLATING FROM FISH TO HUMANS
Despite the power of new technologies, there are substantial fun-
damental challenges to translatingCNSdrugdiscovery fromﬁsh to
humans. Most investigational new drugs fail when they are ﬁnally
tested (for efﬁcacy) in humans (Paul et al., 2010). There are many
reasons why preclinical predictions from any model system would
fail to translate, but lack of rigor should not be one of them.
Inefﬁcient animal studies contribute to publication bias,
decrease scientiﬁc rigor, and limit the drug discovery process.
Compared to zebraﬁsh, studies in larger animals, like mice, are
relatively expensive and require substantial amounts of test com-
pounds. Due to these costs, some large-animal studies tend to be
underpowered, which contributes to irreproducible results (Lan-
dis et al., 2012). Zebraﬁsh enable a level of rigor and reproducibility
that can be difﬁcult to achieve in larger model organisms, sim-
ply because the assays can be easily reproduced on larger scales.
Hypotheses can be tested on thousands of animals, rather than
just a handful, at small cost in time and other resources. For exam-
ple, treating a single mouse (at 10 mg/kg) requires approximately
100X more compound than is needed to treat a well of zebraﬁsh
(at 10 μM). When researchers increase sample size it becomes
easier to ﬁnd true signals amongst the noise. However, even if
new compounds can be discovered with reproducible effects on
zebraﬁsh behavior, substantial challenges remain to translate these
discoveries for improving human health.
Many compounds work in humans, many work in zebraﬁsh,
and some fraction is likely towork in both–although the exact level
of overlap is difﬁcult to predict (Figure 3). Humans and zebraﬁsh
are closely related (Howe et al., 2013), but there are many differ-
ences at the phenotypic, neuronal network, and molecular levels.
When a new bioactive compound is ﬁrst discovered in zebraﬁsh,
it will be difﬁcult to predict its potential therapeutic utility in
humans. Many compounds that appear to work well in mice and
other animal models subsequently fail to translate to humans. The
same will surely be true of zebraﬁsh. The problem is especially
relevant in neuropharmacology, where CNS disorders are poorly
understood and difﬁcult to model. Despite the challenges, in the
upcoming years we are likely to see at least a few compounds
identiﬁed in zebraﬁsh screens translate from bench to bedside.
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